Sale!

Systems Biology in Cancer Immunotherapy 1st Edition by Mahbuba Rahman 1681083078 9781681083070

Name: Systems Biology in Cancer Immunotherapy 1st Edition by Mahbuba Rahman 1681083078 9781681083070
SKU: EB-51573788
Availability: InStock

Original price was: $50.00.Current price is: $25.00.

Systems Biology in Cancer Immunotherapy 1st Edition Mahbuba Rahman Digital Instant Download

Author(s): Mahbuba Rahman

ISBN(s): 9781681083070, 1681083078

Edition: 1

File Details: PDF, 5.01 MB

Year: 2016

Language: English

SKU: EB-51573788 Category: Uncategorized Tag: Mahbuba Rahman

Description

Systems Biology in Cancer Immunotherapy 1st Edition by Mahbuba Rahman – Ebook PDF Instant Download/Delivery: 1681083078, 9781681083070
Full download Systems Biology in Cancer Immunotherapy 1st Edition after payment

Product details:

ISBN 10: 1681083078
ISBN 13: 9781681083070
Author: Mahbuba Rahman

Over the past decades, systems biology approaches have been applied in different areas of life science research including oncology. Researchers now understand the hallmarks of cancer cells such as abnormal cell growth, inflammation, dysregulated metabolic pathways and drug resistance properties at a molecular level. Systems biology approaches have enabled researchers to investigate cancer immunology by identifying cancer related biomarkers on immune cells, and to study the effect of different therapies in tissue cultures and mouse models. Systems Biology in Cancer Immunotherapy explains the scope of systems biology in understanding the immune response to neoplasms. The book introduces readers to the concepts crucial to cancer immunology before delving into the applied systems biology topics such as the metabolic pathways in cancer cells, the biomolecular roles of signal transduction molecules and immunotherapy. A brief conclusion at the end also provides some information from a clinical and commercial perspective on cancer immunotherapy. This volume is intended as an introductory reference for life science and medical students, researchers and academics interested in the application of systems biology to the immune system in cancer patients.

Systems Biology in Cancer Immunotherapy 1st Table of contents:

INTRODUCTION
BASICS OF THE HUMAN IMMUNO SYSTEM
Origin and Formation of the Immune System
CANCER IMMUNOLOGY
IMMUNO-SURVEILLANCE
Innate Immune System in Antitumor Response
Natural Killer (NK) Cells
Macrophages
Dendritic Cells
NKT Cells
γδT cells
Granulocytes
Adaptive Immune System in Anti-tumor Response
B Lymphocytes
T Lymphocytes
Mechanism of Antitumor T-cell Response
Tumor Specific (TSA) and Tumor Associated Antigens (TAA)
Antigens Resulting from Mutation
Antigens Encoded by Cancer-germline Genes
Viral Antigens
Differentiation Antigens
Over-expressed Antigens
Regulatory T Cells in Antitumor Response
Natural Killer Cells
Important Cytokines
Mediators of Natural Immunity
Mediators of Adaptive Immunity
Stimulators of Haematopoiesis
Cytokines Involved in Antitumor Response
Antitumor Effector Mechanism Involving Cytotoxic Mechanisms
Links Between Adaptive and Innate Immunity
Toll-like Receptor (TLR) Signalling
Specific Interplay of Innate and Adaptive Antitumor Immunity
IMMUNE-ESCAPE
Signalling Defects in Anti-tumor T Cells
Tumor Derived Factors
Chemokines in Promoting Cancer Development
Tumor Associated Myeloid Derived Suppressor Cells
Antigen Specific T-cell Tolerance
Regulatory T (Treg) Cells
IMMUNE-EVASION
Circulating Tumor Cells
CONCLUSION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Cancer Metabolism: A Perspective on the Involvement of the Immune System and Metabolic Pathways in C
INTRODUCTION
METABOLIC REPROGRAMMING OF THE IMMUNE CELLS IN TUMOR MICROENVIRONMENT
METABOLIC REPROGRAMMING AND IMMUNE SUPPRESSION IN TUMOR MICROENVIRONMENT
METABOLITES ORIGINATING FROM CELLULAR METABOLISM
Glucose Metabolism
Arginine Metabolism
Tryptophan Metabolism
Reactive Oxygen Species
Cytokines Associated with Tumor Progression
Leptin
Signaling Pathways Associated with Tumor Progression
Autophagy Pathway
CONCLUSION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Signal Transduction Molecules and Pathways in Cancer: Implication of the Immune System in Modulating
INTRODUCTION
SIGNALING MOLECULES ASSOCIATED WITH CANCER DEVELOPMENT
JAK-STAT
K-ras
MYC
p53
SIGNALING PATHWAYS ASSOCIATED WITH CANCER DEVELOPMENT
Apoptosis Pathway
Autophagy Pathway
CONCLUSION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Cancer Immunotherapy
INTRODUCTION
CHEMOTHERAPY DRUGS AND THE IMMUNE SYSTEM
Immuno-modulation of Chemotherapy Drugs
IMMUNOTHERAPY AND THE IMMUNE SYSTEM
NON-SPECIFIC CANCER IMMUNOTHERAPY AND ADJUVANTS
Bacillus Calmette-Guerin (BCG)
Levamisole
Cytokines
Interferon-α
Interleukins
Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)
MONOCLONAL ANTIBODIES
Naked Monoclonal Antibodies
Alemtuzumab (Campath®)
Ipilimumab (Yervoy®)
Bevacizumab (Avastin®)
Cetuximab (Erbitux®)
Ofatumumab (Arzerra®)
Panitumumab (Vactibix®)
Rituximab (Rituxan®)
Trastuzumab (Herceptin®)
Conjugated Monoclonal Antibodies
Radiolabeled Antibodies
Yttrium-90 Ibritumomab Tiuxetan (Zevalin®)
Iodine-131 Tositumomab (Bexxar®)
Chemolabeled Antibodies
Toxin attached Antibodies
Bispecific Monoclonal Antibodies
CANCER VACCINES
Viral Vaccines
Therapeutic Vaccines
Dendritic Cell Vaccines
Adoptive Cellular Therapy
Idiotype Vaccines for B-cell Malignancies
IMMUNOTHERAPY IN DEVELOPMENT
Adoptive T-cell Therapy
Targeting Immunomodulatory Molecules
Immune Checkpoint Blockade
Inhibitory Immune Checkpoints
Co-stimulatory Receptors
Killer Inhibitory Receptors
Combination Therapy
Combining Immune Checkpoint Inhibitors
Combining Immunomodulation with Chemotherapies
CONCLUSION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Systems Biology Approach in Cancer Immuno-therapy
INTRODUCTION
CHALLENGES IN CANCER IMMUNOTHERAPY
Challenges in Biomarker Identification
Challenges with Combination Therapy
Challenges with Animal Models
TECHNOLOGIES OF SYSTEMS BIOLOGY USED IN CANCER IMMUNOTHERAPY
Genomics
Transcriptomics
Proteomics
Metabolomics
Computational Analysis
APPLICATION OF SYSTEMS BIOLOGY APPROACH IN CANCER IMMUNOTHERAPY
Discovery of New Targets
Understanding Therapeutic Mechanism of Action (MoA)
Assessment of Antigen Spread or Epitope Spread
Lymphocyte Receptor Sequencing and Monitoring of T-cell clones
Biomarker Identification
Therapeutic Biomarkers in the Tumor Environment
Biomarkers of Post-treatment
Model Validation
Advancing Personalized Medicine
Combination Therapy
CONCLUSION
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Perspectives
INTRODUCTION
CHALLENGES WITH MARKETING, CLINICAL TRIAL AND SAFETY ISSUE
FUTURE DIRECTIONS
CONFLICT OF INTEREST
ACKNOWLEDGEMENTS
REFERENCES
Subject Index
Back Cover